A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer

Samuel J. Vidal, Veronica Rodriguez-Bravo, S. Aidan Quinn, Ruth Rodriguez-Barrueco, Amaia Lujambio, Estrelania Williams, Xiaochen Sun, Janis delaIglesia-Vicente, Albert Lee, Benjamin Readhead, Xintong Chen, Matthew Galsky, Berta Esteve, Daniel P. Petrylak, Joel T. Dudley, Raul Rabadan, Jose M. Silva, Yujin Hoshida, Scott W. Lowe, Carlos Cordon-CardoJosep Domingo-Domenech

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Elucidating the determinants of aggressiveness in lethal prostate cancer may stimulate therapeutic strategies that improve clinical outcomes. We used experimental models and clinical databases to identify GATA2 as a regulator of chemotherapy resistance and tumorigenicity in this context. Mechanistically, direct upregulation of the growth hormone IGF2 emerged as a mediator of the aggressive properties regulated byGATA2. IGF2 in turn activated IGF1R and INSR as well as a downstream polykinase program. The characterization of this axis prompted a combination strategy whereby dual IGF1R/INSR inhibition restored the efficacy of chemotherapy and improved survival in preclinical models. These studies reveal a GATA2-IGF2 aggressiveness axis in lethal prostate cancer and identify a therapeutic opportunity in this challenging disease.

Original languageEnglish (US)
Pages (from-to)223-239
Number of pages17
JournalCancer Cell
Volume27
Issue number2
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Drug Therapy
Growth Hormone
Theoretical Models
Up-Regulation
Databases
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this

Vidal, S. J., Rodriguez-Bravo, V., Quinn, S. A., Rodriguez-Barrueco, R., Lujambio, A., Williams, E., ... Domingo-Domenech, J. (2015). A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer. Cancer Cell, 27(2), 223-239. https://doi.org/10.1016/j.ccell.2014.11.013

A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer. / Vidal, Samuel J.; Rodriguez-Bravo, Veronica; Quinn, S. Aidan; Rodriguez-Barrueco, Ruth; Lujambio, Amaia; Williams, Estrelania; Sun, Xiaochen; delaIglesia-Vicente, Janis; Lee, Albert; Readhead, Benjamin; Chen, Xintong; Galsky, Matthew; Esteve, Berta; Petrylak, Daniel P.; Dudley, Joel T.; Rabadan, Raul; Silva, Jose M.; Hoshida, Yujin; Lowe, Scott W.; Cordon-Cardo, Carlos; Domingo-Domenech, Josep.

In: Cancer Cell, Vol. 27, No. 2, 01.01.2015, p. 223-239.

Research output: Contribution to journalArticle

Vidal, SJ, Rodriguez-Bravo, V, Quinn, SA, Rodriguez-Barrueco, R, Lujambio, A, Williams, E, Sun, X, delaIglesia-Vicente, J, Lee, A, Readhead, B, Chen, X, Galsky, M, Esteve, B, Petrylak, DP, Dudley, JT, Rabadan, R, Silva, JM, Hoshida, Y, Lowe, SW, Cordon-Cardo, C & Domingo-Domenech, J 2015, 'A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer', Cancer Cell, vol. 27, no. 2, pp. 223-239. https://doi.org/10.1016/j.ccell.2014.11.013
Vidal SJ, Rodriguez-Bravo V, Quinn SA, Rodriguez-Barrueco R, Lujambio A, Williams E et al. A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer. Cancer Cell. 2015 Jan 1;27(2):223-239. https://doi.org/10.1016/j.ccell.2014.11.013
Vidal, Samuel J. ; Rodriguez-Bravo, Veronica ; Quinn, S. Aidan ; Rodriguez-Barrueco, Ruth ; Lujambio, Amaia ; Williams, Estrelania ; Sun, Xiaochen ; delaIglesia-Vicente, Janis ; Lee, Albert ; Readhead, Benjamin ; Chen, Xintong ; Galsky, Matthew ; Esteve, Berta ; Petrylak, Daniel P. ; Dudley, Joel T. ; Rabadan, Raul ; Silva, Jose M. ; Hoshida, Yujin ; Lowe, Scott W. ; Cordon-Cardo, Carlos ; Domingo-Domenech, Josep. / A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer. In: Cancer Cell. 2015 ; Vol. 27, No. 2. pp. 223-239.
@article{8608e3e24b274d31b2a0dfc5e4662c51,
title = "A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer",
abstract = "Elucidating the determinants of aggressiveness in lethal prostate cancer may stimulate therapeutic strategies that improve clinical outcomes. We used experimental models and clinical databases to identify GATA2 as a regulator of chemotherapy resistance and tumorigenicity in this context. Mechanistically, direct upregulation of the growth hormone IGF2 emerged as a mediator of the aggressive properties regulated byGATA2. IGF2 in turn activated IGF1R and INSR as well as a downstream polykinase program. The characterization of this axis prompted a combination strategy whereby dual IGF1R/INSR inhibition restored the efficacy of chemotherapy and improved survival in preclinical models. These studies reveal a GATA2-IGF2 aggressiveness axis in lethal prostate cancer and identify a therapeutic opportunity in this challenging disease.",
author = "Vidal, {Samuel J.} and Veronica Rodriguez-Bravo and Quinn, {S. Aidan} and Ruth Rodriguez-Barrueco and Amaia Lujambio and Estrelania Williams and Xiaochen Sun and Janis delaIglesia-Vicente and Albert Lee and Benjamin Readhead and Xintong Chen and Matthew Galsky and Berta Esteve and Petrylak, {Daniel P.} and Dudley, {Joel T.} and Raul Rabadan and Silva, {Jose M.} and Yujin Hoshida and Lowe, {Scott W.} and Carlos Cordon-Cardo and Josep Domingo-Domenech",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.ccell.2014.11.013",
language = "English (US)",
volume = "27",
pages = "223--239",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "2",

}

TY - JOUR

T1 - A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer

AU - Vidal, Samuel J.

AU - Rodriguez-Bravo, Veronica

AU - Quinn, S. Aidan

AU - Rodriguez-Barrueco, Ruth

AU - Lujambio, Amaia

AU - Williams, Estrelania

AU - Sun, Xiaochen

AU - delaIglesia-Vicente, Janis

AU - Lee, Albert

AU - Readhead, Benjamin

AU - Chen, Xintong

AU - Galsky, Matthew

AU - Esteve, Berta

AU - Petrylak, Daniel P.

AU - Dudley, Joel T.

AU - Rabadan, Raul

AU - Silva, Jose M.

AU - Hoshida, Yujin

AU - Lowe, Scott W.

AU - Cordon-Cardo, Carlos

AU - Domingo-Domenech, Josep

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Elucidating the determinants of aggressiveness in lethal prostate cancer may stimulate therapeutic strategies that improve clinical outcomes. We used experimental models and clinical databases to identify GATA2 as a regulator of chemotherapy resistance and tumorigenicity in this context. Mechanistically, direct upregulation of the growth hormone IGF2 emerged as a mediator of the aggressive properties regulated byGATA2. IGF2 in turn activated IGF1R and INSR as well as a downstream polykinase program. The characterization of this axis prompted a combination strategy whereby dual IGF1R/INSR inhibition restored the efficacy of chemotherapy and improved survival in preclinical models. These studies reveal a GATA2-IGF2 aggressiveness axis in lethal prostate cancer and identify a therapeutic opportunity in this challenging disease.

AB - Elucidating the determinants of aggressiveness in lethal prostate cancer may stimulate therapeutic strategies that improve clinical outcomes. We used experimental models and clinical databases to identify GATA2 as a regulator of chemotherapy resistance and tumorigenicity in this context. Mechanistically, direct upregulation of the growth hormone IGF2 emerged as a mediator of the aggressive properties regulated byGATA2. IGF2 in turn activated IGF1R and INSR as well as a downstream polykinase program. The characterization of this axis prompted a combination strategy whereby dual IGF1R/INSR inhibition restored the efficacy of chemotherapy and improved survival in preclinical models. These studies reveal a GATA2-IGF2 aggressiveness axis in lethal prostate cancer and identify a therapeutic opportunity in this challenging disease.

UR - http://www.scopus.com/inward/record.url?scp=84922788911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922788911&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2014.11.013

DO - 10.1016/j.ccell.2014.11.013

M3 - Article

C2 - 25670080

AN - SCOPUS:84922788911

VL - 27

SP - 223

EP - 239

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 2

ER -